Not "limit", rather "efficacy":
Once we hit 4000mg, assuming there are no clinical adverse reactions, we could (technically) successfully treat a subject that has sepsis.
I think this will attract widespread attention, as from this point on Recce 327 starts to look less like a risk, and more like an opportunity. i.e. F.O.M.O. will build.
All I.M.O. of course.
Ann: Positive safety data from 4th Cohort -Phase I Clinical Trial, page-17
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $115.8M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | 50.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.5¢ | 800 | 1 |
View Market Depth
| Last trade - 09.46am 12/08/2024 (20 minute delay) ? |
| RCE (ASX) Chart |
Day chart unavailable